IGF-2 LR3 (1mg)

What is IGF-2 LR3?

IGF-2 LR3 is a research-market catalog name. This catalog lists a 1mg vial, but the exact amino-acid construct represented by the LR3 label has not been confirmed from an original supplier specification or a matching lot identity report.

Listed vial contents: 1mg. These are supplied quantities, not administration doses. Current pricing and availability are shown in the strength selector.

Which identity should I verify?

Construct pending. Obtain an original specification naming the target sequence and theoretical mass, plus a matching lot LC-MS result and quantitative report. Until then, IGF-2 LR3 must not be treated as a confirmed analog of IGF-1 LR3.

What mechanisms are being studied?

Native IGF-II can signal through IGF-system receptors, including insulin receptor isoform A. That parent-molecule biology does not prove the structure, receptor selectivity, binding-protein affinity or persistence of an unconfirmed material sold as IGF-2 LR3.

What are the research questions?

• Analytical assignment of the marketed LR3 construct
• Comparison with native IGF-II after identity confirmation
• Receptor and binding-protein studies using a defined reference material

What does the published work describe?

Belfiore and colleagues reviewed insulin-receptor isoforms and described IGF-II signaling through insulin receptor isoform A. This is background evidence for native IGF-II biology. No direct peer-reviewed paper validating the specific IGF-2 LR3 construct represented by this catalog item was identified.

Experimental models in the cited papers

• Review of insulin-receptor isoform biology; not a study of this catalog construct

What could future research explore?

The first research question is analytical: define the target sequence, calculate its theoretical mass and compare it with observed intact-mass data from the same lot. Only then could receptor signaling, binding-protein interactions or pharmacokinetics be investigated without borrowing conclusions from IGF-1 LR3 or native IGF-II.

These are research directions, not established applications of the product sold here.

What are the limits of this evidence?

The name, photo and 1mg label do not establish sequence, mass, purity or quantity. Product is currently undergoing testing. Results will be reported once available. Construct-specific pharmacokinetic, binding-protein and receptor-selectivity claims are therefore not made for this inventory.

Study references

1. Belfiore A, et al. Insulin Receptor Isoforms in Physiology and Disease: An Updated View. Endocr Rev. 2017. PMID 28973479

How should I check lot documentation?

Match the product, strength and lot to an original analysis document. Literature describes experimental findings; it does not verify the contents of this inventory. A report is evidence only for the product, strength and lot it names.

How is IGF-2 LR3 handled in the lab?

Plan a IGF-2 LR3 stock solution from the sequence, the listed molecular weight and, when reported for the same lot, net peptide content. Test-dissolve a small portion first, store the powder sealed, cold and dry, and split solutions into single-use aliquots. These are laboratory handling notes, not administration guidance.

• Peptide solubility: choosing a lab solvent
• Stock solution molarity and concentration math
• Lyophilized storage, aliquoting and freeze-thaw
• Fmoc vs Boc synthesis and the impurities they leave